• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxamides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxamides

Comprehensive Overview of Lazabemide Hydrochloride (CAS No. 103878-83-7): Mechanism, Applications, and Research Insights

Lazabemide Hydrochloride (CAS No. 103878-83-7) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), a key enzyme involved in neurotransmitter metabolism. This compound has garnered significant attention in neurological research, particularly for its potential therapeutic applications in neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. The pharmacological profile of Lazabemide Hydrochloride makes it a subject of interest for researchers exploring novel treatments for cognitive decline and motor dysfunction.

In recent years, the search for neuroprotective agents has intensified due to the rising global prevalence of age-related neurological conditions. Lazabemide Hydrochloride stands out due to its ability to modulate dopamine levels without the dietary restrictions associated with non-selective MAO inhibitors. This specificity reduces the risk of adverse effects like the "cheese effect," a common concern with older MAO inhibitors. Researchers are also investigating its potential synergy with L-DOPA and other dopaminergic therapies, addressing a frequent query in neurology forums and academic discussions.

The compound's chemical structure features a benzamide core, contributing to its high bioavailability and blood-brain barrier permeability. Studies highlight its neuroprotective properties in preclinical models, where it reduces oxidative stress and mitochondrial dysfunction—key factors in neurodegeneration. These findings align with current trends in precision medicine, as scientists seek targeted therapies for subpopulations of patients with specific biomarkers or genetic profiles.

From a synthetic chemistry perspective, Lazabemide Hydrochloride (CAS No. 103878-83-7) is synthesized through a multi-step process involving amide bond formation and salt stabilization. Its physicochemical properties, including solubility and stability under physiological conditions, make it suitable for oral administration. Pharmaceutical developers often inquire about its formulation compatibility, especially for extended-release preparations—a topic frequently searched in drug development databases.

Beyond neurodegeneration, exploratory research suggests Lazabemide Hydrochloride may influence neuroinflammation pathways, a hot topic in glial cell research. Its interaction with microglia and astrocytes could open new avenues for treating neuropsychiatric conditions like depression, though clinical evidence remains limited. This dual potential—addressing both motor and non-motor symptoms—positions it as a versatile candidate in central nervous system (CNS) drug discovery.

In the context of drug repurposing, a strategy gaining traction in pharmaceutical R&D, Lazabemide Hydrochloride has been evaluated for off-label applications. Computational studies using AI-driven molecular docking platforms (a frequently searched term in bioinformatics circles) predict interactions with additional targets like sigma receptors, hinting at broader therapeutic utility. However, rigorous clinical validation is needed to substantiate these predictions.

Quality control protocols for Lazabemide Hydrochloride emphasize HPLC-based purity assays, reflecting industry standards for small-molecule therapeutics. Stability studies under varying pH and temperature conditions are critical, as degradation products could compromise efficacy—a concern raised in pharmacopoeia guidelines and regulatory submissions.

As the scientific community prioritizes translational research, Lazabemide Hydrochloride exemplifies the bridge between bench-side discoveries and clinical applications. Its evolving role underscores the importance of enzyme-targeted therapies in modern medicine, while unanswered questions about its long-term effects fuel ongoing investigations—addressing common queries in patient advocacy groups and medical conferences.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)